@article{Correa-Gallego2014129,

title = {Minimally-invasive vs open pancreaticoduodenectomy: Systematic review and meta-analysis},

author = {Camilo Correa-Gallego and Helen E. Dinkelspiel and Isabel Sulimanoff and Sarah Fisher and Eduardo F. Viñuela and T. Peter Kingham and Yuman Fong and Ronald P. Dematteo and Michael I. D'Angelica and William R. Jarnagin and Peter J. Allen},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84890805005&doi=10.1016%2fj.jamcollsurg.2013.09.005&partnerID=40&md5=a41b1f312d9f8097083bea6008d542c9},

doi = {10.1016/j.jamcollsurg.2013.09.005},

issn = {18791190},

year  = {2014},

date = {2014-01-01},

urldate = {2014-01-01},

journal = {Journal of the American College of Surgeons},

volume = {218},

number = {1},

pages = {129 – 139},

note = {Cited by: 130},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Figueras20131597,

title = {Randomized clinical trial of pancreaticogastrostomy versus pancreaticojejunostomy on the rate and severity of pancreatic fistula after pancreaticoduodenectomy},

author = {J. Figueras and L. Sabater and P. Planellas and E. Muñoz-Forner and S. Lopez-Ben and L. Falgueras and C. Sala-Palau and M. Albiol and J. Ortega-Serrano and E. Castro-Gutierrez},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84885396863&doi=10.1002%2fbjs.9252&partnerID=40&md5=2849faaa1e042000e51c75b491c7741a},

doi = {10.1002/bjs.9252},

issn = {13652168},

year  = {2013},

date = {2013-01-01},

urldate = {2013-01-01},

journal = {British Journal of Surgery},

volume = {100},

number = {12},

pages = {1597 – 1605},

abstract = {Background Anastomotic leakage of pancreaticojejunostomy (PJ) remains the single most important source of morbidity after pancreaticoduodenectomy (PD). The primary aim of this randomized clinical trial comparing PG with PJ after PD was to test the hypothesis that invaginated PG would result in a lower rate and severity of pancreatic fistula. Methods Patients undergoing PD were randomized to receive either a duct-to-duct PJ or a double-layer invaginated PG. The primary endpoint was the rate of pancreatic fistula, using the definition of the International Study Group on Pancreatic Fistula. Secondary endpoints were the evaluation of severe abdominal complications (Clavien-Dindo grade IIIa or above), endocrine and exocrine function. Results Of 123 patients randomized, 58 underwent PJ and 65 had PG. The incidence of pancreatic fistula was significantly higher following PJ than for PG (20 of 58 versus 10 of 65 respectively; P = 0·014), as was the severity of pancreatic fistula (grade A: 2 versus 5 per cent; grade B-C: 33 versus 11 per cent; P = 0·006). The hospital readmission rate for complications was significantly lower after PG (6 versus 24 per cent; P = 0·005), weight loss was lower (P = 0·025) and exocrine function better (P = 0·022). Conclusion The rate and severity of pancreatic fistula was significantly lower with this PG technique compared with that following PJ. Registration number: ISRCTN58328599 (http://www.controlled-trials.com). This pancreaticogastrostomy technique is superior © 2013 British Journal of Surgery Society Ltd. Published by John Wiley & Sons Ltd.},

note = {Cited by: 135},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Peng20121478,

title = {Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma},

author = {Peter Peng and Omar Hyder and Amin Firoozmand and Peter Kneuertz and Richard D. Schulick and Donghang Huang and Martin Makary and Kenzo Hirose and Barish Edil and Michael A. Choti and Joseph Herman and John L. Cameron and Christopher L. Wolfgang and Timothy M. Pawlik},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84864083215&doi=10.1007%2fs11605-012-1923-5&partnerID=40&md5=60b20c437380abc43424bba029aa5a39},

doi = {10.1007/s11605-012-1923-5},

issn = {1091255X},

year  = {2012},

date = {2012-01-01},

urldate = {2012-01-01},

journal = {Journal of Gastrointestinal Surgery},

volume = {16},

number = {8},

pages = {1478 – 1486},

abstract = {Introduction: Assessing patient-specific risk factors for long-term mortality following resection of pancreatic adenocarcinoma can be difficult. Sarcopenia-the measurement of muscle wasting-may be a more objective and comprehensive patient-specific factor associated with long-term survival. Methods: Total psoas area (TPA) was measured on preoperative cross-sectional imaging in 557 patients undergoing resection of pancreatic adenocarcinoma between 1996 and 2010. Sarcopenia was defined as the presence of a TPA in the lowest sex-specific quartile. The impact of sarcopenia on 90-day, 1-year, and 3-year mortality was assessed relative to other clinicopathological factors. Results: Mean patient age was 65.7 years and 53.1 % was male. Mean TPA among men (611 mm2/m2) was greater than among women (454 mm2/m2). Surgery involved pancreaticoduodenectomy (86.0 %) or distal pancreatectomy (14.0 %). Mean tumor size was 3.4 cm; 49. 9 % and 88.5 % of patients had vascular and perineural invasion, respectively. Margin status was R0 (59.0 %) and 77.7 % patients had lymph node metastasis. Overall 90-day mortality was 3.1 % and overall 1- and 3-year survival was 67.9 % and 35.7 %, respectively. Sarcopenia was associated with increased risk of 3-year mortality (HR = 1.68; P < 0.001). Tumor-specific factors such as poor differentiation on histology (HR = 1.75), margin status (HR = 1.66), and lymph node metastasis (HR = 2.06) were associated with risk of death at 3-years (all P < 0.001). After controlling for these factors, sarcopenia remained independently associated with an increased risk of death at 3 years (HR = 1.63; P < 0.001). Conclusions: Sarcopenia was a predictor of survival following pancreatic surgery, with sarcopenic patients having a 63 % increased risk of death at 3 years. Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors. © 2012 The Society for Surgery of the Alimentary Tract.},

note = {Cited by: 383; All Open Access, Green Open Access},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Winter2012169,

title = {Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades},

author = {Jordan M. Winter and Murray F. Brennan and Laura H. Tang and Michael I. D'Angelica and Ronald P. Dematteo and Yuman Fong and David S. Klimstra and William R. Jarnagin and Peter J. Allen},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856462406&doi=10.1245%2fs10434-011-1900-3&partnerID=40&md5=509a8bbafcb4d892cf6bcec264dbc058},

doi = {10.1245/s10434-011-1900-3},

issn = {15344681},

year  = {2012},

date = {2012-01-01},

urldate = {2012-01-01},

journal = {Annals of Surgical Oncology},

volume = {19},

number = {1},

pages = {169 – 175},

abstract = {Background: Randomized trials have demonstrated a benefit associated with adjuvant therapy for pancreatic cancer, and retrospective studies have demonstrated improvements in postoperative mortality. The purpose of this study was to evaluate whether these improvements could be identified in a cohort of patients who underwent resection for pancreatic cancer at a single institution over three decades. Methods: Short- (30 days), intermediate- (1 year), and long-term survival were compared between decades. Long-term survival focused on patients who survived at least 1 year to minimize the effects of perioperative mortality and patient selection. Results: Between 1983 and 2009, 1147 pancreatic resections were performed for ductal adenocarcinoma, including 123 resections in the 1980s, 399 in the 1990s, and 625 in the 2000s. The 30-day mortality rates were 4.9%, 1.5% (P = 0.03 vs. 1980s), and 1.3% (P = 0.007 vs. 1980s). The 1-year mortality rates were 42%, 31% (P < 0.001 vs. 1980s), and 24% (P < 0.001 vs. 1980s and 1990s). In the group of patients who survived 1 year, the overall survivals were 23.2 months, 25.6 months (P = 0.6 vs. 1980s), and 24.5 months (P = 0.2 vs. 1980s). In a multivariate analysis adjusted for pathologic features, the decade of resection was not a significant predictor of long-term survival (hazard ratio = 1.1},

note = {Cited by: 254},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Pawlik2007610,

title = {Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer},

author = {Timothy M. Pawlik and Ana L. Gleisner and John L. Cameron and Jordan M. Winter and Lia Assumpcao and Keith D. Lillemoe and Christopher Wolfgang and Ralph H. Hruban and Richard D. Schulick and Charles J. Yeo and Michael A. Choti},

url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247218441&doi=10.1016%2fj.surg.2006.12.013&partnerID=40&md5=8109ad6d086869f4638eff9018f3e924},

doi = {10.1016/j.surg.2006.12.013},

issn = {00396060},

year  = {2007},

date = {2007-01-01},

urldate = {2007-01-01},

journal = {Surgery},

volume = {141},

number = {5},

pages = {610 – 618},

abstract = {Background: The presence or absence of lymph node metastases is known to be an important prognostic factor for patients with pancreatic cancer. Few studies have investigated the ratio of the number of lymph nodes harboring metastatic cancer to the total number of lymph nodes examined (lymph node ratio [LNR]) with regard to outcome after pancreaticoduodenectomy for ductal cancer of the pancreas. Methods: Between 1995 and 2005, a total of 905 patients underwent pancreaticoduodenectomy for pancreatic adenocarcinoma. Demographics, operative data, number of lymph nodes evaluated, number of lymph nodes with metastatic carcinoma, LNR, pathologic margin status, and long-term survival were analyzed. Results: There were 187 (20.7%) of the 905 patients who had negative peripancreatic lymph nodes (N0), whereas 718 (79.3%) of the 905 patients had lymph node metastases (N1). The median number of lymph nodes evaluated in the N0 group was 15 versus 18 in the N1 group (P = .12). At median follow-up of 24 months, the median survival for all patients was 17.4 months, and the 5-year actuarial survival rate was 16.1%. Patients with lymph node metastases had a shorter median overall survival (16.5 months) compared with patients with negative lymph nodes (25.3 months; P = .001). Compared with the total number of lymph nodes examined or total number of lymph node metastases, LNR was the most compelling predictor of survival. As the LNR increased, median overall survival decreased (LNR = 0, 25.3 months; LNR > 0 to 0.2, 21.7 months; LNR > 0.2 to 0.4, 15.3 months; LNR > 0.4, 12.2 months; P = .001). After adjusting for other factors associated with survival, LNR remained an independent predictor of overall survival (P < .001). Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival. LNR should be considered when stratifying patients in future clinical trials. © 2007 Mosby, Inc. All rights reserved.},

note = {Cited by: 355},

keywords = {},

pubstate = {published},

tppubtype = {article}

}